comparemela.com

Latest Breaking News On - Yvette petillon - Page 3 : comparemela.com

[Ad hoc announcement pursuant to Art 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% At week 24, 100% of CT-388.

F Hoffmann-La Roche Ltd: Roche announces FDA approval of one of the first HPV self-collection solutions in the U S , expanding access and screening options to help eliminate cervical cancer

F Hoffmann-La Roche Ltd: Roche announces FDA approval of one of the first HPV self-collection solutions in the U S , expanding access and screening options to help eliminate cervical cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Roche announces FDA approval of one of the first HPV self-collection solutions in the U S , expanding access and screening options to help eliminate cervical cancer

Roche announces FDA approval of one of the first HPV self-collection solutions in the U S , expanding access and screening options to help eliminate cervical cancer
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone News provided by Share this article starting in Austria, bringing more discretion and simplicity to the life of people with diabetes. ●  in the same place where they keep their diabetes data. ●  People with diabetes are given the possibility to share insulin pump data with their healthcare professionals for a more integrated and personalised approach to diabetes care. - Picture is available at AP Images (http://www.apimages.com) - BASEL, Switzerland, May 19, 2021 /PRNewswire/ Roche today announced the launch of the mySugr Pump Control, a new module within the mySugr app. The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus. The mySugr Pump Control is an important building block within Roche s strategy of integrated Persona

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy - Roche and Lilly will integrate data from Lilly s connected insulin pen solution into the mySugr app in several countries. - Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals. - By collaborating with Lilly, Roche accelerates growth of its open ecosystem enabling its strategy of integrated Personalised Diabetes Management (iPDM). BASEL, Switzerland, May 6, 2021 /PRNewswire/ Roche today announced that it has signed a collaboration agreement with Eli Lilly and Company, a global leader in diabetes care delivering innovative solutions including medicines and technologies, to work towards optimising the management of insulin pen therapy. By collaborating with Lilly, Roche follows its ambition to create an open ecosystem including its own and partner devices, sol

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.